ArriVent BioPharma, Inc. Common Stock (AVBP) - Total Assets
Based on the latest financial reports, ArriVent BioPharma, Inc. Common Stock (AVBP) holds total assets worth $326.56 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of ArriVent BioPharma, Inc. Common Stock for net asset value and shareholders' equity analysis.
ArriVent BioPharma, Inc. Common Stock - Total Assets Trend (2021–2024)
This chart illustrates how ArriVent BioPharma, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
ArriVent BioPharma, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (September 2024)
ArriVent BioPharma, Inc. Common Stock's total assets of $326.56 Million consist of 82.6% current assets and 17.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.0% |
| Accounts Receivable | $500.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how ArriVent BioPharma, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AVBP company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ArriVent BioPharma, Inc. Common Stock's current assets represent 82.6% of total assets in 2024, a decrease from 99.8% in 2021.
- Cash Position: Cash and equivalents constituted 27.0% of total assets in 2024, down from 86.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
ArriVent BioPharma, Inc. Common Stock Competitors by Total Assets
Key competitors of ArriVent BioPharma, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
ArriVent BioPharma, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.90 | 19.28 | 21.84 |
| Quick Ratio | 14.90 | 19.28 | 21.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $299.66 Million | $277.24 Million | $174.26 Million |
ArriVent BioPharma, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between ArriVent BioPharma, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.96 |
| Latest Market Cap to Assets Ratio | 3.28 |
| Asset Growth Rate (YoY) | 68.6% |
| Total Assets | $274.94 Million |
| Market Capitalization | $902.41 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values ArriVent BioPharma, Inc. Common Stock's assets at a significant premium (3.28x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: ArriVent BioPharma, Inc. Common Stock's assets grew by 68.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ArriVent BioPharma, Inc. Common Stock (2021–2024)
The table below shows the annual total assets of ArriVent BioPharma, Inc. Common Stock from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-09-30 | $274.94 Million | +68.57% |
| 2023-09-30 | $163.10 Million | -10.79% |
| 2022-09-30 | $182.83 Million | +324.81% |
| 2021-09-30 | $43.04 Million | -- |
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutati… Read more